| Chimeric antigen receptor T-cell therapy—assessment and management of toxicities SS Neelapu, S Tummala, P Kebriaei, W Wierda, C Gutierrez, FL Locke, ... Nature reviews Clinical oncology 15 (1), 47-62, 2018 | 2075 | 2018 |
| Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update BJ Schneider, J Naidoo, BD Santomasso, C Lacchetti, S Adkins, ... Journal of clinical oncology 39 (36), 4073-4126, 2021 | 794 | 2021 |
| Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit'ALL' SS Neelapu, S Tummala, P Kebriaei, W Wierda, FL Locke, Y Lin, N Jain, ... Nature reviews Clinical oncology 15 (4), 218-218, 2018 | 208 | 2018 |
| Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma CC Pinnix, JR Gunther, BS Dabaja, P Strati, P Fang, MC Hawkins, ... Blood Advances 4 (13), 2871-2883, 2020 | 175 | 2020 |
| Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline BD Santomasso, LJ Nastoupil, S Adkins, C Lacchetti, BJ Schneider, ... Journal of clinical oncology 39 (35), 3978-3992, 2021 | 152 | 2021 |
| Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma P Strati, S Ahmed, F Furqan, LE Fayad, HJ Lee, SP Iyer, R Nair, ... Blood, The Journal of the American Society of Hematology 137 (23), 3272-3276, 2021 | 124 | 2021 |
| Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma P Strati, A Varma, S Adkins, LJ Nastoupil, JR Westin, FB Hagemeister, ... Haematologica 106 (10), 2667, 2021 | 110 | 2021 |
| Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma P Strati, LJ Nastoupil, J Westin, LE Fayad, S Ahmed, NH Fowler, ... Blood advances 4 (16), 3943-3951, 2020 | 75 | 2020 |
| Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection P Strati, LJ Nastoupil, LE Fayad, F Samaniego, S Adkins, SS Neelapu Blood, The Journal of the American Society of Hematology 133 (26), 2800-2802, 2019 | 55 | 2019 |
| CAR T-cell therapy: adverse events and management S Adkins Journal of the advanced practitioner in oncology 10 (Suppl 3), 21, 2019 | 50 | 2019 |
| Safety of CAR T-cell therapy in kidney transplant recipients O Mamlouk, R Nair, SP Iyer, A Edwards, SS Neelapu, RE Steiner, ... Blood, The Journal of the American Society of Hematology 137 (18), 2558-2562, 2021 | 34 | 2021 |
| Recognizing and grading CAR T-cell toxicities: an advanced practitioner perspective S Sievers, G Watson, S Johncy, S Adkins Frontiers in Oncology 10, 885, 2020 | 29 | 2020 |
| Adult Survivorship: Considerations following CAR T-cell therapy. J Buitrago, S Adkins, M Hawkins, K Iyamu, T van Oort Clinical Journal of Oncology Nursing 23 (2), 2019 | 25 | 2019 |
| Safety of axicabtagene ciloleucel CD19 CAR T-cell therapy in elderly patients with relapsed or refractory large B-cell lymphoma D Sano, LJ Nastoupil, NH Fowler, L Fayad, FB Hagemeister, HJ Lee, ... Blood 132, 96, 2018 | 21 | 2018 |
| Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma SS Neelapu, S Adkins, SM Ansell, J Brody, MS Cairo, JW Friedberg, ... Journal for immunotherapy of cancer 8 (2), 2020 | 14 | 2020 |
| Clinical and radiological correlates of neurotoxicity after standard of care axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma P Strati, S Tummala, LJ Nastoupil, JR Westin, L Fayad, S Ahmed, ... Blood 134, 765, 2019 | 12 | 2019 |
| Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS. K Anand, E Burns, D Sano, SR Pingali, J Westin, LJ Nastoupil, HJ Lee, ... Journal of Clinical Oncology 37 (15_suppl), 2540-2540, 2019 | 11 | 2019 |
| Hematopoietic recovery and immune reconstitution after axi-cel CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma. P Strati, S Adkins, LJ Nastoupil, J Westin, FB Hagemeister, NH Fowler, ... Journal of Clinical Oncology 37 (15_suppl), 7545-7545, 2019 | 10 | 2019 |
| A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma P Strati, A Jallouk, Q Deng, X Li, L Feng, R Sun, S Adkins, S Johncy, ... Blood Advances 7 (21), 6785-6789, 2023 | 9 | 2023 |
| Comparative review of 30 day non-relapse mortality (NRM) in B-cell lymphomas associated with anti-CD19 chimeric antigen receptor T-cells (CAR-T) from FDA database, clinical … E Burns, K Anand, JR Westin, SRK Pingali, J Ensor, D Sano, LJ Nastoupil, ... Blood 134, 1931, 2019 | 9 | 2019 |
